News
News
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions...
Read moreDetails
NextGen Healthcare: A Goldmine for M&A Arbitrageurs in the Healthcare Landscape?
Speculation around the company's future has sent ripples across the market, especially after its stock price surged in response to...
Read moreDetails
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides
NanoViricides, Inc. (NYSE American: NNVC) a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
Read moreDetailsLongeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-BTM in Hypoplastic Left Heart Syndrome
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today...
Read moreDetails
Trio Petroleum Corp Lauds California Supreme Court’s Affirmation of Measure Z’s Defeat, a Decision Favorable to California’s Energy Independence
Trio Petroleum Corp. (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, comments today that it...
Read moreDetailsPresenting on the Emerging Growth Conference on August 9 & 10 Register Now
EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 60th Emerging Growth Conference on August 9,...
Read moreDetails
HomeStreet Bank Exploring A Sale: Is It Worth Considering For Quick M&A Linked Trade?
HomeStreet Bank, a Seattle-based micro-cap lender that focuses on mortgages and commercial real estate loans, is exploring a potential sale.
Read moreDetails
DSS Inc. Announces Distribution Date of August 8, 2023 for Spinoff of Impact BioMedical Inc.
DSS, Inc. (NYSE American: DSS), a multinational company operating nine business divisions through strategic acquisitions and development to build shareholder...
Read moreDetails
Muscle Maker, Inc. and AGGIA LLC FZ Amend Services Agreement
New Agreement to Reduce Expenses Related to Stock Issuance and Enhance Profit Potential
Read moreDetails
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
NanoViricides, Inc. (NYSE American: NNVC),
Read moreDetails